These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 25706873)
41. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo. Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094 [TBL] [Abstract][Full Text] [Related]
43. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo. Baek JM; Kim JY; Yoon KH; Oh J; Lee MS Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631 [TBL] [Abstract][Full Text] [Related]
44. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815 [TBL] [Abstract][Full Text] [Related]
45. DGKζ Downregulation Enhances Osteoclast Differentiation and Bone Resorption Activity Under Inflammatory Conditions. Iwazaki K; Tanaka T; Hozumi Y; Okada M; Tsuchiya R; Iseki K; Topham MK; Kawamae K; Takagi M; Goto K J Cell Physiol; 2017 Mar; 232(3):617-624. PubMed ID: 27312515 [TBL] [Abstract][Full Text] [Related]
46. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages. Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094 [TBL] [Abstract][Full Text] [Related]
47. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides. Amcheslavsky A; Bar-Shavit Z J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377 [TBL] [Abstract][Full Text] [Related]
48. Berberine Sulfate Attenuates Osteoclast Differentiation through RANKL Induced NF-κB and NFAT Pathways. Zhou L; Song F; Liu Q; Yang M; Zhao J; Tan R; Xu J; Zhang G; Quinn JM; Tickner J; Xu J Int J Mol Sci; 2015 Nov; 16(11):27087-96. PubMed ID: 26580592 [TBL] [Abstract][Full Text] [Related]
49. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189 [TBL] [Abstract][Full Text] [Related]
50. Cloning and characterization of osteoclast precursors from the RAW264.7 cell line. Cuetara BL; Crotti TN; O'Donoghue AJ; McHugh KP In Vitro Cell Dev Biol Anim; 2006; 42(7):182-8. PubMed ID: 16948499 [TBL] [Abstract][Full Text] [Related]
51. Regulation of osteoclast-mediated bone resorption by microRNA. Ji L; Li X; He S; Chen S Cell Mol Life Sci; 2022 May; 79(6):287. PubMed ID: 35536437 [TBL] [Abstract][Full Text] [Related]
52. Folliculin Regulates Osteoclastogenesis Through Metabolic Regulation. Baba M; Endoh M; Ma W; Toyama H; Hirayama A; Nishikawa K; Takubo K; Hano H; Hasumi H; Umemoto T; Hashimoto M; Irie N; Esumi C; Kataoka M; Nakagata N; Soga T; Yao M; Kamba T; Minami T; Ishii M; Suda T J Bone Miner Res; 2018 Oct; 33(10):1785-1798. PubMed ID: 29893999 [TBL] [Abstract][Full Text] [Related]
54. Tea polyphenols inhibit rat osteoclast formation and differentiation. Oka Y; Iwai S; Amano H; Irie Y; Yatomi K; Ryu K; Yamada S; Inagaki K; Oguchi K J Pharmacol Sci; 2012; 118(1):55-64. PubMed ID: 22186621 [TBL] [Abstract][Full Text] [Related]
55. The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis. Gao Y; Ge W Cell Death Dis; 2018 Jan; 9(2):33. PubMed ID: 29348610 [TBL] [Abstract][Full Text] [Related]
56. Cutting Edge: EZH2 Promotes Osteoclastogenesis by Epigenetic Silencing of the Negative Regulator IRF8. Fang C; Qiao Y; Mun SH; Lee MJ; Murata K; Bae S; Zhao B; Park-Min KH; Ivashkiv LB J Immunol; 2016 Jun; 196(11):4452-4456. PubMed ID: 27183582 [TBL] [Abstract][Full Text] [Related]
58. Sexually Dimorphic Increases in Bone Mass Following Tissue-specific Overexpression of Runx1 in Osteoclast Precursors. Díaz-Hernández ME; Kinter CW; Watson SR; Mella-Velazquez G; Kaiser J; Liu G; Khan NM; Roberts JL; Lorenzo J; Drissi H Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35880727 [TBL] [Abstract][Full Text] [Related]
59. Arginine methylation of PPP1CA by CARM1 regulates glucose metabolism and affects osteogenic differentiation and osteoclastic differentiation. Zhang L; Jiao G; You Y; Li X; Liu J; Sun Z; Li Q; Dai Z; Ma J; Zhou H; Li G; Meng C; Chen Y Clin Transl Med; 2023 Sep; 13(9):e1369. PubMed ID: 37649137 [TBL] [Abstract][Full Text] [Related]
60. Both aerobic glycolysis and mitochondrial respiration are required for osteoclast differentiation. Li B; Lee WC; Song C; Ye L; Abel ED; Long F FASEB J; 2020 Aug; 34(8):11058-11067. PubMed ID: 32627870 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]